US6300873022 - Common Stock
NANOVIRICIDES INC
NYSEARCA:NNVC (7/3/2024, 7:23:56 PM)
After market: 1.7599 0 (-0.01%)1.76
-0.02 (-1.12%)
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. The firm's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. The company is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.
NANOVIRICIDES INC
1 Controls Drive
Shelton CONNECTICUT 06484
P: 12039376137
CEO: Anil Diwan
Employees: 7
Website: http://www.nanoviricides.com/
Which stocks are moving on Friday?
Top movers in Friday's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!
NNVC stock results show that Nanoviricides beat analyst estimates for earnings per share the third quarter of 2024.
Here you can normally see the latest stock twits on NNVC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: